-
Mashup Score: 10
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 76
Despite a prevailing dogma wherein antibody drug conjugates (ADCs) increase the maximum tolerated dose of potent cytotoxin payloads while lowering the minimum effective dose, mounting clinical evidence argues that the tolerated doses of ADCs are not significantly different from those of related small molecules. Nonetheless, when dosed at or near the maximum tolerated dose, certain ADCs demonstrate improved efficacy. Understanding the challenges and opportunities for this class of biotherapeutics will help improve the design of next-generation ADCs.
Source: www.cell.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 76
Despite a prevailing dogma wherein antibody drug conjugates (ADCs) increase the maximum tolerated dose of potent cytotoxin payloads while lowering the minimum effective dose, mounting clinical evidence argues that the tolerated doses of ADCs are not significantly different from those of related small molecules. Nonetheless, when dosed at or near the maximum tolerated dose, certain ADCs demonstrate improved efficacy. Understanding the challenges and opportunities for this class of biotherapeutics will help improve the design of next-generation ADCs.
Source: www.cell.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 76
Despite a prevailing dogma wherein antibody drug conjugates (ADCs) increase the maximum tolerated dose of potent cytotoxin payloads while lowering the minimum effective dose, mounting clinical evidence argues that the tolerated doses of ADCs are not significantly different from those of related small molecules. Nonetheless, when dosed at or near the maximum tolerated dose, certain ADCs demonstrate improved efficacy. Understanding the challenges and opportunities for this class of biotherapeutics will help improve the design of next-generation ADCs.
Source: www.cell.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
PURPOSE Although patients with metastatic breast cancer (MBC) have been living longer with the advent of more effective treatments such as targeted therapy and immunotherapy, the disease remains incurable, and most patients will undergo therapy indefinitely. When beginning therapy, patients are typically prescribed dose often based upon the maximum tolerated dose identified in phase I clinical trials. However, patients’ perspectives about tolerability and willingness to discuss individualized dosing of drugs upon initiation of a new regimen and throughout the course of treatment have not been comprehensively evaluated. METHODS Patient advocates and medical oncologists from the Patient-Centered Dosing Initiative (PCDI) developed a survey to ascertain the prevalence and severity of MBC patients’ treatment-related side effects, the level of patient-physician communication, mitigation strategies, perception about the relative efficacy of higher versus lower doses, and willingness to discus
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 47
PURPOSE Although patients with metastatic breast cancer (MBC) have been living longer with the advent of more effective treatments such as targeted therapy and immunotherapy, the disease remains incurable, and most patients will undergo therapy indefinitely. When beginning therapy, patients are typically prescribed dose often based upon the maximum tolerated dose identified in phase I clinical trials. However, patients’ perspectives about tolerability and willingness to discuss individualized dosing of drugs upon initiation of a new regimen and throughout the course of treatment have not been comprehensively evaluated. METHODS Patient advocates and medical oncologists from the Patient-Centered Dosing Initiative (PCDI) developed a survey to ascertain the prevalence and severity of MBC patients’ treatment-related side effects, the level of patient-physician communication, mitigation strategies, perception about the relative efficacy of higher versus lower doses, and willingness to discus
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
The TROP2-directed antibody-drug conjugate Dato-DXd demonstrated promising activity in heavily pre-treated patients (pts) with inoperable or metastatic HR+/HER2-BC in the Phase 1 TROPION-PanTumor01 trial (NCT03401385). Here we report primary PFS results from the global, Phase 3 TROPION-Breast01 trial (NCT05104866).
Source: www.annalsofoncology.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 44FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations - 5 month(s) ago
The FDA has approved capivasertib (Truqap) in combination with fulvestrant (Faslodex) for the treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more PIK3CA, AKT1, or PTEN alteration, as detected by an FDA-approved test, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 44FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations - 5 month(s) ago
The FDA has approved capivasertib (Truqap) in combination with fulvestrant (Faslodex) for the treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more PIK3CA, AKT1, or PTEN alteration, as detected by an FDA-approved test, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 15SWOG CTP Partners with AstraZeneca on TROPION-Breast03 Trial - SWOG Clinical Trials Partnerships - 6 month(s) ago
SWOG Cancer Research Network Clinical Trials Partnerships (SWOG CTP) is collaborating with AstraZeneca and Daiichi Sankyo as the scientific partners on
Source: www.swogctp.orgCategories: General Medicine News, Hem/OncsTweet
Pivotal phase 3 clinical trials with Dato-DXd ongoing, including Tropion-B03 enrolling pts with residual disease after neoadjuvant therapy for TNBC. Collaboration @SWOG @KalinskyKevin @evaciruelos @DrDawnHershman https://t.co/Sv2Hrl2ejG #bcsm https://t.co/od8KW3rZa3